Eli Lilly and Co. (LLY) Monday announced the completion of its acquisition of Versanis Bio. The deal will add Versanis' lead asset, Bimagrumab to Eli Lilly. Bimagrumab is currently in a Phase 2b study alone and in combination with semaglutide in adults living overweight or obese.
As per the agreement, Versanis shareholders could receive up to $1.925 billion in cash, inclusive of the upfront payment and other milestone payments.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.